FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
15 oct. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies...
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
06 août 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
24 juil. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative...
Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
02 juil. 2024 08h00 HE
|
Annovis Bio, Inc.
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a...
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
27 juin 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
11 juin 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for...
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
05 juin 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Alzheimer’s Disease Diagnostics & Treatment Market Revenues to Reach US$11.9 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Persistence Market Research
17 janv. 2024 05h00 HE
|
Persistence Market Research
New York, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Market Size & Overview: The global market for Alzheimer's disease diagnostics and treatment is projected to experience a compound annual growth rate...
Vyant Bio Announces Adjournment of Special Meeting of Stockholders
20 sept. 2023 13h00 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 20, 2023 (the...
Enhancing Care: Expansion of Alpers Disease Treatment Market Size On its Path to US$ 1.90 Billion by 2030, at a 4.57% of CAGR.
07 juin 2023 09h13 HE
|
Zion Market Research
Houston, TX, June 07, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Alpers Disease Treatment Market By Diagnosis (Molecular Genetic Testing, Laboratory...